Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: An alternative cell-based antitumor vaccine

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 1818-1828

  Ko, Hyun Jeong ^a   Lee, Jung Mi ^a   Kim, Yeon Jeong ^a   Kim, Yun Sun ^a   Lee, Kyoo A ^a   Kang, Chang Yuil ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; B7 ANTIGEN; BIOLOGICAL MARKER; CANCER VACCINE; CD11B ANTIGEN; CD1D ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DERIVED SUPPRESSOR CELL VACCINE; PEPTIDE VACCINE; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HOST CELL; IN VIVO STUDY; MONOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CYTOLOGY; CYTOTOXICITY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; TRANSPLANTATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; MYELOID CELLS; NATURAL KILLER T-CELLS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 61449220940     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802430     Document Type: Article

References (61)

1. Schultze, J. L., S. Grabbe, and M. S. von Bergwelt-Baildon. 2004. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 25: 659-664.
2. Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10: 475-480.
3. Banchereau, J., B. Schuler-Thurner, A. K. Palucka, and G. Schuler. 2001. Dendritic cells as vectors for therapy. Cell 106: 271-274.
4. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52-58.
5. Chaperot, L., M. Chokri, M. C. Jacob, P. Drillat, F. Garban, H. Egelhofer, J. P. Molens, J. J. Sotto, J. C. Bensa, and J. Plumas. 2000. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia 14: 1667-1677.
6. Peng, J. C., R. Thomas, and L. K. Nielsen. 2005. Generation and maturation of dendritic cells for clinical application under serum-free conditions. J. Immunother. 28: 599-609.
7. Zobywalski, A., M. Javorovic, B. Frankenberger, H. Pohla, E. Kremmer, I. Bigalke, and D. J. Schendel. 2007. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl. Med. 5: 18.
8. Almand, B., J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone, and D. I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166: 678-689.
9. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166.
10. Serafini, P., I. Borrello, and V. Bronte. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16: 53-65.
11. Bronte, V., P. Serafini, C. De Santo, I. Marigo, V. Tosello, A. Mazzoni, D. M. Segal, C. Staib, M. Lowel, G. Sutter, et al. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170: 270-278.
12. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/ CD28 costimulation. J. Immunol. 165: 779-785.
13. Bronte, V., P. Serafini, A. Mazzoni, D. M. Segal, and P. Zanovello. 2003. L-Arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24: 302-306.
14. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172: 989-999.
15. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumorbearing host. Cancer Res. 66: 1123-1131.
16. hi suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179: 5228-5237.
17. Sawanobori, Y., S. Ueha, M. Kurachi, T. Shimaoka, J. E. Talmadge, J. Abe, Y. Shono, M. Kitabatake, K. Kakimi, N. Mukaida, and K. Matsushima. 2008. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111: 5457-5466.
18. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
19. Chang, D. H., K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201: 1503-1517.
20. Fujii, S., K. Shimizu, M. Kronenberg, and R. M. Steinman. 2002. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 3: 867-874.
21. Chung, Y., B. S. Kim, Y. J. Kim, H. J. Ko, S. Y. Ko, D. H. Kim, and C. Y. Kang. 2006. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res. 66: 6843-6850.
22. Kim, Y. J., H. J. Ko, Y. S. Kim, D. H. Kim, S. Kang, J. M. Kim, Y. Chung, and C. Y. Kang. 2008. α-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int. J. Cancer 122: 2774-2783.
23. + regulatory T cells. J. Exp. Med. 202: 885-891.
24. Chang, S. Y., K. C. Lee, S. Y. Ko, H. J. Ko, and C. Y. Kang. 2004. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int. J. Cancer 111: 86-95.
25. Ko, H. J., Y. J. Kim, Y. S. Kim, W. S. Chang, S. Y. Ko, S. Y. Chang, S. Sakaguchi, and C. Y. Kang. 2007. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67: 7477-7486.
26. + dendritic cells mediate cross-tolerance toward intestinal antigens. Blood 106: 201-206.
27. Gupta, G. P., and J. Massague. 2006. Cancer metastasis: building a framework. Cell 127: 679-695.
28. Gupta, G. P., D. X. Nguyen, A. C. Chiang, P. D. Bos, J. Y. Kim, C. Nadal, R. R. Gomis, K. Manova-Todorova, and J. Massague. 2007. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765-770.
29. + plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat. Immunol. 8: 1207-1216.
30. Naik, S. H., P. Sathe, H. Y. Park, D. Metcalf, A. I. Proietto, A. Dakic, S. Carotta, M. O'Keeffe, M. Bahlo, A. Papenfuss, et al. 2007. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat. Immunol. 8: 1217-1226.
31. Hegde, S., X. Chen, J. M. Keaton, F. Reddington, G. S. Besra, and J. E. Gumperz. 2007. NKT cells direct monocytes into a DC differentiation pathway. J. Leukocyte Biol. 81: 1224-1235.
32. + bone marrow hematopoietic progenitor cells. Blood 92: 118-128.
33. Luft, T., K. C. Pang, E. Thomas, P. Hertzog, D. N. Hart, J. Trapani, and J. Cebon. 1998. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161: 1947-1953.
34. Fujii, S., K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198: 267-279.
35. Shimizu, K., A. Goto, M. Fukui, M. Taniguchi, and S. Fujii. 2007. Tumor cells loaded with α-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J. Immunol. 178: 2853-2861.
36. Chung, Y., H. Qin, C. Y. Kang, S. Kim, L. W. Kwak, and C. Dong. 2007. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 110: 2013-2019.
37. Shimizu, K., Y. Kurosawa, M. Taniguchi, R. M. Steinman, and S. Fujii. 2007. Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J. Exp. Med. 204: 2641-2653.
38. + NKT regulatory cells and IL-13. Int. J. Cancer 114: 80-87.
39. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, and J. A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1: 515-520.
40. Stewart, T. J., M. J. Smyth, G. J. Fernando, I. H. Frazer, and G. R. Leggatt. 2003. Inhibition of early tumor growth requires Jα18-positive (natural killer T) cells. Cancer Res. 63: 3058-3060.
41. Crowe, N. Y., M. J. Smyth, and D. I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196: 119-127.
42. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-βproduction and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocytemediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
43. Terabe, M., C. Khanna, S. Bose, F. Melchionda, A. Mendoza, C. L. Mackall, L. J. Helman, and J. A. Berzofsky. 2006. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-β. Cancer Res. 66: 3869-3875.
44. Ambrosino, E., M. Terabe, R. C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J. A. Berzofsky. 2007. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J. Immunol. 179: 5126-5136.
45. Berzofsky, J. A., and M. Terabe. 2008. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J. Immunol. 180: 3627-3635.
46. Jahng, A., I. Maricic, C. Aguilera, S. Cardell, R. C. Halder, and V. Kumar. 2004. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199: 947-957.
47. Renukaradhya, G. J., M. A. Khan, M. Vieira, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz. 2008. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 111: 5637-5645.
48. Gerosa, F., B. Baldani-Guerra, C. Nisii, V. Marchesini, G. Carra, and G. Trinchieri. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195: 327-333.
49. Piccioli, D., S. Sbrana, E. Melandri, and N. M. Valiante. 2002. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195: 335-341.
50. Martin-Fontecha, A., L. L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, and F. Sallusto. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming. Nat. Immunol. 5: 1260-1265.
51. Ravetch, J. V., and L. L. Lanier. 2000. Immune inhibitory receptors. Science 290: 84-89.
52. Grimm, E. A., A. Mazumder, H. Z. Zhang, and S. A. Rosenberg. 1982. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823-1841.
53. Lucas, M., W. Schachterle, K. Oberle, P. Aichele, and A. Diefenbach. 2007. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26: 503-517.
54. + cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection. J. Immunol. 177: 6747-6757.
55. Coquet, J. M., S. Chakravarti, K. Kyparissoudis, F. W. McNab, L. A. Pitt, B. S. McKenzie, S. P. Berzins, M. J. Smyth, and D. I. Godfrey. 2008. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc. Natl. Acad. Sci. USA 105: 11287-11292.
56. + T-cell-independent pathway for antitumor CTL induction. Blood 106: 338-344.
57. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201: 779-791.
58. Chaput, N., G. Darrasse-Jeze, A. S. Bergot, C. Cordier, S. Ngo-Abdalla, D. Klatzmann, and O. Azogui. 2007. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J. Immunol. 179: 4969-4978.
59. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6: 1219-1227.
60. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198: 235-247.
61. Serafini, P., S. Mgebroff, K. Noonan, and I. Borrello. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68: 5439-5449.